HIKMA, A CONVINCINGLY DIFFERENT PHARMA (ADD; 12% UPSIDE)
23/12/20 -"Since our last endorsement in April 2020, it has been a seesaw ride for the generic drugs manufacturer, Hikma (Add, UK). While the reiteration of its FY20 targets (in May), at a time when peers were ..."
Pages
54
Language
English
Published on
23/12/20
You may also be interested by these reports :
28/07/26
The Q2 results were ahead of expectations, backed by strong growth across GSK’s key focus areas. The management maintained its full-year guidance. ...
27/07/26
The Q2 26 results were largely in line with the street’s expectations. Strong growth in oncology, respiratory, immunology and rare disease treatments ...
23/07/26
Despite FX headwinds, the Q2 results were ahead of the street’s expectations. The performance was driven by drugs across therapeutic areas, and the ...
22/07/26
Lonza published its 1H results, with a strong operating performance but a mixed revenue outcome. The group grew by +16% (CER) YoY, with strong FX ...